Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

Summary

The proposed study represents a crucial and important stage in translating basic research to strategies for treating nicotine dependence. The investigation addresses an important public health issue by testing an intervention - informed by basic research - that may lead to a more effective and efficient treatment for smokers. The expected findings should provide initial effect size data for the addition of isradipine to an integrated psychosocial/behavioral and pharmacological smoking cessation intervention for smokers, and thus provide the necessary data for a large-scale follow-up trial.

Timeline

Start

2020-01-22

Primary completion

2023-06-14

Completion

2023-06-14

Publications

• Young CC, Papini S, Minami H, Morikawa H, Otto MW, Roache JD, Smits JAJ. Isradipine augmentation of virtual reality cue exposure therapy for tobacco craving: a triple-blind randomized controlled trial. Neuropsychopharmacology. 2024 Oct;49(11):1711-1718. doi: 10.1038/s41386-024-01872-9. Epub 2024 May 24.

Drugs

Indications